Subject
Obstetrics and Gynecology,Reproductive Medicine
Reference8 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer,2019
2. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study;Solomon;Lancet Respir Med,2022
3. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J Clin Oncol,2012
4. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion;Rimkunas;Clin Cancer Res,2012
5. Lorviqua 25 mg Summary of product characteristics. Accessed 05/02, 2023.